Skip to main content
. 2024 Apr 9;115(6):1834–1850. doi: 10.1111/cas.16171

FIGURE 1.

FIGURE 1

Elevated AIM2 expression in immune and epithelial cells of human KRAS‐mutant LAC lung biopsies. (A) Gene expression of inflammasome‐associated components in KRAS‐mutant (MUT) tumor (T; n = 138) and KRAS wild‐type (WT) tumor (n = 375) versus non‐tumor (NT; n = 59) tissues from TCGA LAC patients. False discovery rate adjusted p‐values: *p < 0.05, ***p < 0.001, ****p < 0.0001. (B) Representative images of AIM2‐stained lung sections from non‐cancer (N) and tumor (T) tissues from an Australian LAC patient cohort stratified into KRAS wild‐type or mutant. Scale bars: 100 μm. The graph depicts quantification of AIM2‐positive cells/high‐power field (HPF) in human lung biopsies (n = 5–6/group). (C) Representative immunofluorescence images of lung tumor sections from a KRAS‐mutant LAC patient co‐stained for AIM2 (green) and total immune cells (CD45, red, top panel), alveolar type‐II cells (surfactant protein‐C (SPC), red, middle panel), and club cells (CC10, red, bottom panel). DAPI nuclear staining is blue. Scale bars: 50 μm. White arrowheads, representative dual‐positive AIM2‐expressing immune (top panel) and alveolar type‐II (middle panel) cells.